Tag:

Parkinson's

Latest Headlines

Latest Headlines

Encapsulated Alzheimer's, Parkinson's-treating growth factors implanted directly in the brain

Scientists in Spain have now developed small particles with the ability to encapsulate growth factors when implanted in the brain, which could ultimately reverse the effects of these diseases by spurring the growth of new, healthy neurons.

Can't stop gambling or shopping? Parkinson's meds may be to blame, JAMA study finds

When Parkinson's disease patients start taking new meds, doctors go on the lookout for the usual side effects: dizziness, nausea, and the like. But according to a new study, they need to think weird, too. The risk of compulsive behavior--gambling, shopping, sex--is much higher than previously thought.

UPDATED: Acorda snags Phase III Parkinson's drug in $525M cash buyout

Acorda Therapeutics is gambling $525 million on a Phase III-ready Parkinson's treatment, striking an all-cash deal to buy Civitas Therapeutics.

Civitas, NeuroDerm, EyeGate to pursue IPO dreams, combined $165M on the line

Israel's NeuroDerm filed for a stock offering on the basis of its subcutaneous formulation for treating Parkinson's; Civitas, the developer of an inhaled formulation for the disease, is expected to debut on the Nasdaq Sept. 24; and EyeGate Pharmaceuticals, which employs low-voltage electrical current to deliver eye medication, also just filed for an IPO.

Acadia surges after nabbing 'breakthrough' title for late-stage Parkinson's drug

The FDA has just added a fresh boost to Acadia Pharmaceuticals, naming its late-stage Parkinson's drug pimavanserin a "breakthrough" therapy deserving rapid regulatory response as it nears the finish line with a closely watched marketing application.

Parkinson's play Civitas Therapeutics files for an $86M IPO

The S-1 prominently features Civitas' successful Phase IIb study for an inhaled formulation of levodopa, a "rescue" treatment for Parkinson's patients.

Civitas nails $55M venture round for a PhIII Parkinson's study

Civitas Therapeutics has nailed down a substantial $55 million venture round aimed at getting its lead program for Parkinson's through Phase III and onto the market. The Chelsea, MA-based biotech is developing CVT-301, a fast-acting rescue formulation of levodopa that can be self-administered through an inhaler.

Study finds blood-brain barrier opening can be controlled, enabling enhanced drug delivery

Columbia University scientists showed that it is possible to control the size of the blood-brain barrier opening by varying the pressure of an ultrasound beam, a discovery that could herald major breakthroughs in the treatment of neurological diseases.

Affiris clears Phase I with Parkinson's vaccine candidate

Austria-based vaccinemaker Affiris announced that its Parkinson's disease vaccine has met its primary endpoint in a small Phase I safety trial of patients receiving two different doses of the jab.

Phase II trial kicks off for sublingually delivered Parkinson's therapy

A sublingually delivered thin film strip to treat advanced Parkinson's disease kicked off its Phase II clinical trial following discussions with the FDA, Cynapsus Therapeutics announced July 16.